CN106421589A - Traditional Chinese medicinal effective part for decreasing uric acid as well as preparation method and application thereof - Google Patents
Traditional Chinese medicinal effective part for decreasing uric acid as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN106421589A CN106421589A CN201611009850.3A CN201611009850A CN106421589A CN 106421589 A CN106421589 A CN 106421589A CN 201611009850 A CN201611009850 A CN 201611009850A CN 106421589 A CN106421589 A CN 106421589A
- Authority
- CN
- China
- Prior art keywords
- preparation
- rhizoma alpiniae
- alpiniae officinarum
- uric acid
- alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a traditional Chinese medicinal effective part for decreasing uric acid as well as a preparation method and application thereof. The traditional Chinese medicinal effective part is total flavone and a diphenylheptane diarylheptanoid obtained by being extracted and separated from alpinia officinarum hance, and is prepared from the following components of 35wt% to 80 wt% of galangin, 5wt% to 14wt% of galangin-3-O-methyl ether, 1wt% to 7wt% of kaempferol-4'-O-methyl ether and 2wt% to 10wt% of 1-phenyl-7-(3'-methoxyl-4'-hydroxyl)-5-ol-3-heptanone; the sum of the components does not exceed 100 percent. The effective part prepared and obtained by the preparation method provided by the invention is definite and is high in purity. According to the whole preparation method, except for ethanol, other organic solvents are not used; the preparation method is environment-friendly and pollution-free. The industrialized mass production is easily realized in the whole production process. In-vitro and in-vivo pharmacodynamic experiments and preliminary clinical experiments all show that an alpinia-officinarum-hance effective part prepared and obtained by the preparation method provided by the invention has an obvious uric acid decreasing effect. The traditional Chinese medicinal effective part has a quite good effect on a patient suffering from hyperuricemia or gout.
Description
Technical field
The present invention relates to the field of Chinese medicines, particularly to a kind of effective ingredient in Chinese of uric acid resisting and preparation method thereof and should
With.
Background technology
Hyperuricemia refers under normal purine diet state, non-2 empty stomach serum uric acid levels on the same day：Male>420μ
Mol/L, women>360μmol/L.Development with social economy and living-pattern preservation, prevalence of hyperuricemia is alive
In rising trend in the range of boundary.The eighties in 20th century, American-European countries's prevalence of hyperuricemia was 2%～18%.2006, Beijing
The investigation in area shows that the prevalence of male is 13.8%, and women is 6.00%, and the prevalence of some areas adult male is even
Reach 22.6%.According to the report of various places prevalence of hyperuricemia in recent years, the current China of conservative estimation there are about patient 1.2 hundred million,
Account for the 10% of total population.Hyperuricemia is not only the direct inducement of gout, also with metabolism syndrome, 2 patients with type Ⅰ DM, high blood
Pressure, cardiovascular disease, chronic nephropathy etc. are closely related, are the worldwide public health problems seriously threatening human health.Facing
In bed, most Patients with Hyperuricemias do not have any symptom, just because of the feature of asymptomatic hyperuricemia, great majority
Patient is often ignored, thus missing the optimal intervention period of disease, having delayed the course of disease of disease, having caused than more serious
Consequence.Therefore, research and development treatment antihyperuricemic disease drug can improve health level and the life of the mankind comprehensively
Cytokines matter, the medicine of current clinical treatment hyperuricemia is mainly based on Western medicine, evident in efficacy, but untoward reaction is numerous, such as
Gastrointestinal symptom, erythra, liver function injury, bone marrow depression etc., compromise health, in Chinese medicine during treatment simultaneously
A kind of safe and effective and the relatively low uric acid resisting of toxic and side effects medicine is developed in middle selection, has extremely wide market prospect,
And good Social and economic benef@can be created.
Asymptomatic hyperuricemia is defined as only hyperuricemia and no gouty arthritis and uric acid renal calculuss.Gout
Principal pathogenetic reason be monosodium urate crystalline salt (urate crystal) deposition.Although atherosclerosis, hypertension
Relevant with the serum uric acid concentration raising with chronic renal disease, but direct between urate crystal deposition and these diseases
Relation not clear.Research shows, urate crystal body is not only present in each period of gout, and in the high urine of pure
There is also in acidemia patient, it is probably the important interstage that hyperuricemia is developed to gout.Therefore, at present
Think the past hyperuricemia and gout (asymptomatic hyperuricemia, acute gouty arthritises, chronic gout stone pain by stages
Wind) the crucial pathologic basis of this disease can not be reflected.In recent years, advanced imaging method is updated, micropolariscope, super
Sound and dual intensity CT all can high special ground detection monosodium urate crystalline salt.Scholar is had to propose new different clinical staging systems, A
Stage：Hyperuricemia, but the symptom of the evidence that no uric acid list sodium crystal deposits and gout；B-stage：Hyperuricemia, passes through
Microscope or senior imaging deposit to urate crystal, but do not have the symptom of gout；C-stage：The past or current uric acid
Salt crystallization deposition is with the symptom of gout outbreak；The D stage：Chronic gout arthritis or merging tophuses.To hyperuricemia and pain
The modification of the different clinical staging systems of wind has many advantages.This Staging System provides conjunction for potential silent disese examination
The basis of reason.Asymptomatic hyperuricemia urate knot can be detected for simple hyperuricemia by advanced imaging method
The situation of brilliant deposition is classified.Additionally, the revision of this proposal provides a clear and definite emphasis, gout is urate crystal
A kind of chronic disease of deposition, and the strategy of asymptomatic hyperuricemia prevention and treatment will be had influence on, particularly have influence on B
The preventing and treating of stage disease (have urate crystals to deposit, but do not have the symptom of gout).
The effect of uric acid resisting medicine is mainly realized by two ways at present：One kind is suppression uric acid synthesis, another kind of
It is to promote urate excretion.
Allopurinol is uric acid resisting medicine most widely used at present.Allopurinol is competitive xanthine oxidase inhibitor, leads to
Cross the effect of suppression uric acid synthetically produced uric acid resisting.Adverse reactions caused by allopurinol mainly includes gastrointestinal symptom, erythra, liver function energy loss
Evil, bone marrow depression etc., should give to monitor.About 5% patient is not resistant to.Occasionally have and occur serious allopurinol allergy comprehensive
Simulator sickness (allopurinol hypersen sitivitysyndrome, AHS).In potential renal insufficiency patient and adopt thiazine
During class diuretic, this risk increases.The research such as Khanna confirms, AHS close phase with human leucocyte antigen HLA-B5801 gene masculine
Close.Chinese han population HLA-B58 positive rate reaches 6%～8%, and white man is only 2%.Although the incidence rate of AHS only 0.1%, die of illness
Rate is up to 20%.
The representative medicine promoting urate excretion is Benzbromarone.Benzbromarone is applied to constitutional and Secondary cases antihyperuricemic
Disease, gouty arthritises intermission and tophus swell etc..Under normal circumstances, take 6～8 days blood uric acids of Benzbromarone obvious under
Fall, blood uric acid intensity and compliance rate are better than allopurinol.Untoward reaction mainly has：The digestive system such as diarrhoea, stomach discomfort, nausea
Symptom;The skin allergys such as welt, macule, flushing, prurituss；Abnormal liver function and glutamic oxaloacetic transaminase, GOT, glutamate pyruvate transaminase and alkalescence
Phosphatase raises.Show according to national drug adverse reaction monitoring database analysises, in the serious adverse reaction of Benzbromarone, liver damages
Evil problem is than more prominent.
Rhizoma Alpiniae Officinarum（Alpinia officinarum Hance）For Zingiberaceae（Zingiberaceae）Alpinia plants, another name
Little Rhizoma Alpiniae Officinarum, current chart Rhizoma Zingiberis Recens, are a kind of plant resourceses of dietotherapeutic, often cook flavouring agent in Guangdong and country in Southeast Asia and use, are also
One of U.S.'s " generally recognized as safe uses material "（21 CFR Section 182.10, 182.20）, rhizome is used as medicine, existing in China
The cultivation of centuries and medicinal history, have warming stomach for dispelling cold, promoting the circulation of QI to relieve pain effect.But, have with regard to Rhizoma Alpiniae Officinarum uric acid resisting activity
Effect position and its preparation method and application there is no pertinent literature to report at present.
Content of the invention
It is an object of the invention to provide a kind of effective ingredient in Chinese with uric acid resisting, the uric acid resisting of Rhizoma Alpiniae Officinarum can be specified
Target site.
Another object of the present invention is to providing the preparation method of this effective ingredient in Chinese, maximally effective activity can be obtained
Position, and reduce impurity.
A further object of the present invention is to provide this effective ingredient in Chinese in the medicine of preparation treatment hyperuricemia or gout
Application in thing.
The present invention is achieved through the following technical solutions：
A kind of effective ingredient in Chinese of uric acid resisting, it is that the total flavones that in Rhizoma Alpiniae Officinarum, extraction separation obtains become with Diphenylheptane class
Point.
In the effective ingredient in Chinese of above-mentioned uric acid resisting, effective ingredient in Chinese comprise galangin, galangin -3- methyl ether,
Kaempferol -4 '-methyl ether and 1- phenyl -7-（3 '-methoxyl group -4 '-hydroxyl）The main components such as -5- alcohol -3- heptanone.
In the effective ingredient in Chinese of above-mentioned uric acid resisting, main component contained by effective site adopts high performance liquid chromatography to survey
Determine it is preferred that containing galangin 35wt%-80 wt %, galangin -3-O- methyl ether 5 wt %- in this effective ingredient in Chinese
14 wt %, kaempferol -4 '-O- methyl ether 1 wt %-7 wt %, 1- phenyl -7-（3 '-methoxyl group -4 '-hydroxyl）- 5- alcohol -3- heptan
Ketone 2 wt %-10 wt %, its summation is less than 100%.
It is preferred that this preparation method comprises the steps in the preparation method of the effective ingredient in Chinese of above-mentioned uric acid resisting：
Take galangal rhizome to be raw material, with ethanol as solvent extraction, obtain Rhizoma Alpiniae Officinarum alcohol extract；
Rhizoma Alpiniae Officinarum alcohol extract is reclaimed ethanol and/or adds water, so that precipitation is precipitated, standing, leaching precipitate, obtain the effective portion of Rhizoma Alpiniae Officinarum
Position crude product；
Rhizoma Alpiniae Officinarum effective site crude product is added after ethanol solution dissolving, carries out separating using macroporous resin column, with water and ethanol be
Mobile phase carries out eluting, collects certain density alcohol elution, and to its decompression and solvent recovery, after separating out precipitation, filters,
It is dried, recrystallization obtains final product Rhizoma Alpiniae Officinarum effective site.
It is preferred that this preparation method comprises the steps in the preparation method of the effective ingredient in Chinese of above-mentioned uric acid resisting：
Galangal rhizome is taken to be raw material, with ethanol solution 6-10 times amount reflux, extract, 2-4 time of 50%-95%, each 1-3 hour,
Obtain Rhizoma Alpiniae Officinarum alcohol extract；
Rhizoma Alpiniae Officinarum alcohol extract is reclaimed ethanol and is less than 50% to alcohol content, so that precipitation is precipitated, stand more than 6 hours, leaching precipitates
Thing, obtains Rhizoma Alpiniae Officinarum effective site crude product；
Rhizoma Alpiniae Officinarum effective site crude product is added after the dissolving of 45%-65% ethanol solution, using macroporous resin post separation, use successively water,
Any concentration in 50% ethanol solution, the ethanol solution of 65%-90% carries out eluting, collects the ethanol elution of alcohol content 65%-90%
Position, and to its decompression and solvent recovery, after separating out precipitation, filter, be dried, use 50%-90% ethyl alcohol recrystallization, obtaining final product Rhizoma Alpiniae Officinarum has
Effect position.
It is preferred that big pore resin includes various non-polar macroporous resin, low pole macropore in above-mentioned preparation method
Resin or polar macroporous resin.
According to specific embodiments, most preferably, this effective ingredient in Chinese is prepared by the following method：
（1）Galangal rhizome is taken to be raw material, with 85% ethanol, 8 times amount reflux, extract, 3 times, 2 hours every time, filtration, merging filtrate,
Obtain Rhizoma Alpiniae Officinarum alcohol extract；
（2）Alcohol extract reclaims ethanol, adds water to alcohol content 30%, stands 12 hours, and filtration obtains Rhizoma Alpiniae Officinarum effective site crude product；
（3）Rhizoma Alpiniae Officinarum effective site crude product is added after 50% ethanol dissolving, by macroporous resin column, use successively water, 50% ethanol,
85% ethanol carries out eluting, collects 85% ethanol elution, decompression and solvent recovery, after separating out precipitation, filters, be dried, use 60% ethanol
Recrystallization obtains Rhizoma Alpiniae Officinarum effective site, makes preparation with suitable adjuvant.
It is preferred that big pore resin includes D101 type macroporous resin and/or AB-8 type macropore in above-mentioned preparation method
Resin.
The present invention also provides the medicine in preparation treatment hyperuricemia or gout for the effective ingredient in Chinese of above-mentioned uric acid resisting
Application in thing.
The said medicine of the present invention refers to be used the effective ingredient in Chinese of the present invention to make as principle active component
The preparation that can be pharmaceutically accepted, the dosage form of preparation includes but is not limited to：Enema；Tablet, such as sugar coated tablet, Film coated tablets
Agent, enteric coated tablet；Capsule, such as hard capsule, soft capsule；Oral liquid；Mouth containing agent；Granule；Electuary；Pill；Drip
Pill；Powder；Unguentum, such as ointment, plaster；Sublimed preparation；Suspensoid；Powder；Solution, such as injection；Suppository；Put on the skin
Agent；Cream；Spray；Powder spray；Aerosol；Drop；Lozenge and patch.
Prepare various dosage forms adjuvant be selected from cellulose, starch, soluble starch, Icing Sugar, dextrin, Mannitol, Lactose,
One or more of sucrose, Microcrystalline Cellulose etc..Preferably, adjuvant is selected from Microcrystalline Cellulose.Tablet of the present invention, capsule
Agent, oral liquid, mouth containing agent, granule, electuary, pill, drop pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, bolt
Agent, liniment, cream, spray, powder spray, aerosol, drop, lozenge and patch can pass through conventional formulation known in the art
Prepared by means.
Oral Preparation in the said medicine of the present invention can contain conventional adjuvant, such as binding agent, filler, dilute
Release one or more of agent, tablet agent, lubricant, disintegrating agent, coloring agent, flavoring agent and wetting agent, if necessary can be to wherein
Tablet be coated.
The form of liquid oral medicine can be for example aqueouss or oleaginous suspension, solution, Emulsion, syrup or elixir,
Or can be in the dry products being compounded with water or other suitable carrier before use.Described liquid oral medicine can contain routine
Additive, described additive includes：Suspending agent, such as Sorbitol, syrup, methylcellulose, gelatin, hydroxyethyl cellulose,
Carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats；Emulsifying agent, such as lecithin, anhydro sorbitol monooleate
Or arabic gum；Non-aqueous carrier, can be edible oil such as almond oil, fractionated coconut oil；The ester of glycerol, propylene glycol or ethanol；Anti-
Rotten agent, such as para hydroxybenzene methyl ester, propyl p-hydroxybenzoate or sorbic acid, and if necessary, conventional fragrance can be contained
Agent or coloring agent.
For injection, preparation-obtained fluid unit dosage form contains Chinese medicine preparation and the sterile carrier of the present invention.Root
According to the concentration of carrier and Chinese medicine preparation, the Chinese medicine preparation of the present invention can be made finally to be suspended or dissolve.Just preparation injection is molten
For liquid, by dissolving in the carrier Chinese medicine preparation of the present invention, and before being loaded into suitable bottle or ampoule bottle, to it
Carry out filter-sterilized, be then loaded in bottle and seal.Additionally, also can be by conventional adjuvant such as local anesthetic, anti-corrosion
Agent and buffer agent are dissolved in above-mentioned carrier.For the stability of the injection obtained by improving, can be by obtained injection
Freezed, then removed moisture under vacuo.
The present invention further provides the combination of above-mentioned medicine and pharmaceutically acceptable carrier, described pharmaceutically acceptable
Carrier include sugar alcohol, aminoacid, vitamin C, EDETATE SODIUM, Ethylenediaminetetraacetic Acid Calcium Salt, inorganic salt, stearate, mineral acid, organic
One of hydrochlorate, carbohydrates and their derivative, cellulose and its derivates, silicon derivative, surfactant and phospholipid material or
Several combinations；
Described sugar alcohol includes the combination of one or more of Mannitol, Sorbitol, xylitol；
Described aminoacid includes the combination of one or more of Cysteine Hydrochloride, Methionine, glycine；
Described inorganic salt includes the alkali-metal carbonate of monovalence, the alkali-metal acetate of monovalence, the alkali-metal phosphate of monovalence, chlorine
Change one or more of sodium, potassium chloride, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, Calcium Carbonate, calcium bicarbonate
Combination；
Described stearate includes calcium stearate he/ or magnesium stearate；
Described mineral acid includes the combination of one or more of hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid；
Described acylate includes sodium lactate；
Described carbohydrates and their derivative is included as in maltose, glucose, Fructose, dextran, sucrose, Lactose, cyclodextrin, starch
The combination of one or more；
Described silicon derivative includes the combination of one or more of alginate, gelatin, Polyvinylpyrrolidone, glycerol, agar
Described surfactant includes Tween 80 and/or Polyethylene Glycol；
Described phospholipid material includes Kaolin and/or Pulvis Talci.
In above-mentioned application, it will be understood by those skilled in the art that can using when determined according to the concrete condition of patient
The usage of effective ingredient in Chinese of the present invention and consumption.In a preferred embodiment, using as oral solid formulation
When effective ingredient in Chinese of the present invention is used for the treatment of hyperuricemia or gout, it is administered once a day or for several times, is preferably administered one
Secondary, give 0.3g-0.7g every time（Day takes effective dose）, preferably give the effective ingredient in Chinese of the present invention of 0.5g every time.?
When effective ingredient in Chinese of the present invention being used for the control after disease prevention or stable disease, dosage can be reduced as one sees fit, for example, control
Treat 1/2,1/3, the 1/4 of effective dose amount, but not limited to this.
Rhizoma Alpiniae Officinarum alcohol extracting thing is divided into petroleum ether part, dichloromethane position, ethyl acetate extract, n-butyl alcohol by the present invention
Position.It is index using external xanthine oxidase inhibitory activity and internal uric acid resisting activity, guiding separates and determines effective site
And invalid target, determine that effective site is total flavonoid and Diphenylheptane class, and effective site has been carried out composition separation,
Differentiate it is determined that the structure of effective site main component.With main component as target, Rhizoma Alpiniae Officinarum is carried out be suitable for industrialization big
The research of the preparation methoies such as the extraction of production, purification, preparation, obtains its effective site, and carries out internal pharmacodynamics test with just
The clinical trial of step, verifies the pharmacological action of its uric acid resisting, result effect is significant.
Prove beneficial effects of the present invention below by way of experiment.
（1）Rhizoma Alpiniae Officinarum effective site body outer screening test
Take Rhizoma Alpiniae Officinarum 2KG, plus 8 times amount, 85% alcohol reflux 3 times, 2 h every time, filtration, merging filtrate, it is concentrated into no alcohol taste,
Petroleum ether extraction 3 times, each 2000ml, dichloromethane extracts three times, each 2000ml, ethyl acetate extraction three times, every time
2000ml, n-butanol extraction three times, each 1000ml, is finally left water position, by each effective site recycling design to dry, is dried
Obtain petroleum ether part, dichloromethane position, ethyl acetate extract, n-butanol portion, water position.
（2）Xanthine oxidase activity measures
HPLC algoscopy, chromatographic column Diamonsil plus ODS C18-A（250mm 4.6mm×5μm ）Mobile phase flows
It is mutually 0.02mol/LKH2PO4Solution, Detection wavelength 290nm, flow velocity 1.0ml/min measures system, variable concentrations test article
Solution 200 μ l,Xanthine oxidase solution 200μl（0.19u/ml）, hatch 15 minutes for 35 DEG C, add xanthine solution 400 μ
l（1. 0 mmol/L）37 DEG C are reacted 30 minutes, add 1mol/L hydrochloric acid 200ul terminating reaction, and phosphate-buffered salt is settled to
2ml, blank, negative control solution phosphate buffered saline(PBS) replaces sample liquid, and HPLC method measures the generation of uric acid, meter
Calculate suppression ratio.
Vitro Experimental Results show, Rhizoma Alpiniae Officinarum ethyl acetate extract activity is the strongest, can obviously inhibit xanthine oxidase activity,
High dose is close with allopurinol.
（3）Uric acid resisting screening active ingredients in Rhizoma Alpiniae Officinarum body
Weigh appropriate Oteracil Potassium, be suspended with 0.5% CMC-Na solution, be configured to the modeling liquid of 12.5 mg/mL.
Kunming mouse, sub-cage rearing is in interior, room temperature（20～22 DEG C）, relative humidity 35%～50%, free diet,
Drinking-water.After adaptability is raised 5 days, start to be administered.
110 Male Kunming strain mice, are randomly divided into 11 groups by body weight, every group 10, are set to blank group, model
Group, allopurinol group, and 8 groups of Rhizoma Alpiniae Officinarum each position variable concentrations extract dry products.Above-mentioned 11 groups of animals, are placed in metabolic cage,
Free diet, drinking-water, blank and model group gavage gives 0.5% CMC-Na, and the daily gavage of other each group gives corresponding medicine,
Dosage is as 0.2 mL/10g, successive administration 7 days.6th day, except blank group lumbar injection 0.2 mL/10 g's 0.5%
CMC-Na solution, other each group lumbar injection Oteracil Potassium solution.7th day, i.e. 1 h before last dose, blank group lumbar injection
The CMC-Na solution of 0.2 mL/10g 0.5%, other each group lumbar injection Oteracil Potassium solution 0.2 mL/10 g, after 1 h, pluck
Eyeball takes blood, and above-mentioned sample is pressed testing uric acid test kit respectively, added reaction reagent, is measured.Test data SPSS11.5
Software statistics analyze, analysis result with± SD represents.
Can be seen that compared with model group from upper table result, ethyl acetate extract uric acid resisting effect is significant, high dose group drops
Uric acid effect is suitable with allopurinol matched group, high dose be better than low dose group, so speculate Rhizoma Alpiniae Officinarum uric acid resisting effective site with
There is larger dependency in ethyl acetate extract.
（4）The separation of Rhizoma Alpiniae Officinarum ethyl acetate extract main component and structural identification
Take ethyl acetate extract extractum through silica gel column chromatography, recrystallization, prepare that thin layer chromatography etc. is multiple to isolate and purify means therefrom
Separate and obtain 4 main compound：
A）Galangin：This compound is yellow needles（Petroleum ether-ethyl acetate）, 205-206 DEG C of m.p., it is soluble in acetic acid
Ethyl ester, acetone, methanol.Under uviol lamp, 254nm is it is seen that yellow under light；Hydrochloric acid magnesium powder reacting positive, FeCl3Reaction is aobvious dirty green
Color, hydrogen spectrum display three feature phenolic hydroxyl group signals of flavoneδ H12.35 (1H, s), 10.83 (1H, s), 9.63 (1H,
s).δ H8.15 (2H, m), 7.55 (2H, m), 7.50 (1H, m) is B ring proton,δ H6.47 (1H, d,J=
2.0Hz), 6.22 (1H, d,J=2.0Hz) it is 6,8 proton signals of A ring.The physicochemical constant of this compound of consulting literatures
Consistent with galangin with spectral data, therefore authenticating compound is galangin.
B）Nimbecetin -4 '-O- methyl ether：This compound is yellow needles（Petroleum ether-ethyl acetate）, m.p. 226-228
DEG C, it is soluble in ethyl acetate, acetone, methanol.Under uviol lamp, 254nm is it is seen that yellow under light；Hydrochloric acid magnesium powder reacting positive,
FeCl3The aobvious dirty green of reaction, prompting may be flavone compound.
Hydrogen spectrum three phenolic hydroxyl group signals of displayδ H12.43 (1H,s), 10.77 (1H,s), 9.47 (1H,s).δ H
8.15 (2H,d,J=7.0Hz), 7.11 (2H,d,J=7.0Hz) it is B ring proton,δ H6.45 (1H,d,J=2.1Hz),
6.20 (1H,d,J=2.1Hz) it is 6,8 proton signals of A ring,δ H3.84 (3H, s) be methoxyl group hydrogen signal.Consulting literatures
The physicochemical constant of this compound and spectral data are basically identical with nimbecetin -4 '-O- methyl ether, thus authenticating compound be nimbecetin -
4 '-methyl ether
C）Galangin -3-O- methyl ether：This compound is yellow crystal（Petroleum ether-ethyl acetate）, 250-253 DEG C of m.p., easily
It is dissolved in ethyl acetate, acetone.Under uviol lamp, 254nm skin dark stain；Hydrochloric acid magnesium powder reacting positive, FeCl3The aobvious dirty green of reaction, points out
It may be flavone compound.
Hydrogen spectrum two phenolic hydroxyl group signals of displayδ H12.60 (1H,s), 10.95 (1H,s).δ H8.02 (2H,m),
7.58 (3H, m) is B ring proton,δ H6.46 (1H,d,J=1.8Hz), 6.23 (1H, d,J=1.8Hz) for 6, A ring, 8
Proton signal,δ H3.81 (3H, s) be methoxyl group hydrogen signal.The physicochemical constant of this compound of consulting literatures and spectral data with
Galangin -3-O- methyl ether is basically identical, therefore authenticating compound is galangin -3-O- methyl ether.
(1H 500 MHz, 1H 300 MHz, DMSO-d6, δ in ppm, J in Hz)1 1 d 6 δ J
| Position | Galangin | Nimbecetin -4 '-O- methyl ether | Galangin -3-O- methyl ether |
| 6 | 6.22 (d,J=2.1) | 6.20 (d,J=2.1) | 6.23 (d,J=1.8) |
| 8 | 6.47 (d,J=2.1) | 6.46 (d,J=2.1) | 6.46 (d,J=1.8) |
| 2′ | 8.15 (m) | 8.14 (dd, 6.9,J=2.1) | 8.02 (d, m) |
| 3′ | 7.55 (m) | 7.12 (dd, 6.9,J=2.1) | 7.59 (m) |
| 4′ | 7.50 (m) | 7.58 (m) | |
| 5′ | 7.55 (m) | 7.12 (dd, 6.9,J=2.1) | 7.59 (m) |
| 6′ | 8.15 (m) | 8.14 (dd, 6.9,J=2.1) | 8.02 (d,J=6.0, 2.4) |
| 3-OH | 9.63 (s) | 9.47 (s) | |
| 5-OH | 12.35 (s) | 12.43 (s) | 12.60 (s) |
| 7-OH | 10.83 (s) | 10.77 (s) | 10.95 (s) |
| 3-OCH3 | 3.81 (s) | ||
| 4′-OCH3 | 3.84 (s) |
D）1- phenyl -7-（3 '-methoxyl group -4 '-hydroxyl）- 5- alcohol -3- heptanone：This compound is white powder, mp 71-73
DEG C, it is dissolved in chloroform, acetone, methanol.254nm skin dark stain；Iodine displaing yellow；10% concentrated sulphuric acid-aobvious the aeruginouss of vanillin spraying heating, carries
Show that this compound may be Diphenylheptane class.ESI-MS m/z ESI-MS m/z 329[M+H]+, molecular weight is 328.Hydrogen
Spectrum (300MHz, CDCl3) displayδ:5 hydrogen at 7.15-7.26, is the hydrogen of 1 monosubstituted phenyl ring；6.82(1H, d, J=
7.8Hz), 6.66 (2H m) is 1,3,4- trisubstituted benzene ring hydrogen signal；Width unimodal at 5.50, is phenolic hydroxyl group hydrogen；3.87 place 3
Individual hydrogen, unimodal, it is methoxyl group signal on phenyl ring；1 hydrogen, multiplet at 4.04, are Hydrogen Proton signal on oxygen-containing carbon； 2.90-
8 hydrogen signals at 2.55, the respectively hydrogen signal of phenyl ring and carbonyl side methylene；1.64-1.76 2, place hydrogen is fatty hydrogen
Signal, the physicochemical constant of this compound of consulting literatures and spectral data and 1- phenyl -7-（3 '-methoxyl group -4 '-hydroxyl）-5-
Alcohol -3- heptanone is basically identical.
(1H 500 MHz,1H 300 MHz, CDCl3,δin ppm,Jin Hz)
It can be seen that, beneficial effects of the present invention are as follows：
（1）The present invention passes through system solvent partition method and Rhizoma Alpiniae Officinarum is separated polarity different component, external by different component
Anti- xanthine oxidase activity and internal uric acid resisting activity are screened, and determine the main component of possible effective site；Then
With above-mentioned main component as target, carry out meeting product by methods such as alcohol extracting-water precipitating, purification by macroporous resin, ethyl alcohol recrystallization purification
The research of the preparation method that industry metaplasia is produced, this preparation method is enriched with to Rhizoma Alpiniae Officinarum effective site well, is prepared
Effective site purity high, effective site content is in more than 50wt%.
（2）In whole preparation method in addition to ethanol, not using other organic solvents, environment friendly and pollution-free.Macroporous resin can
To reuse, ethanol can be with recycling, and production process is safe, controlled, with low cost, and whole production process is easily achieved
The big production of industrialization.
（3）Using galangin in high effective liquid chromatography for measuring Rhizoma Alpiniae Officinarum effective site, galangin -3- methyl ether, mountain
How phenol -4 '-methyl ether and 1- phenyl -7-（3 '-methoxyl group -4 '-hydroxyl）The content of four main components such as -5- alcohol -3- heptanone,
Specificity is strong, and result is accurately and reliably.
（4）The inhibitory activity to xanthine oxidase for each position of external test Rhizoma Alpiniae Officinarum, measures uric acid life using HPLC method
The appraisement system of one-tenth amount is evaluated, it is to avoid the interfering of uv absorption between spectrophotography each composition, impact measures
The accuracy of result.
（5）In vitro, internal pharmacodynamics test and preliminary clinical trial all show, the height being obtained by preparation method of the present invention
Rhizoma Alpiniae Officinarum effective site has obvious uric acid resisting effect.For hyperuricemia or patient with gout, there is good effect.
Brief description
Fig. 1 is the chromatograms of total flavonoid composition in the sample of ethyl acetate extract under fragmentation state；
Fig. 2 is the chromatograms of total flavonoid composition in the sample 1 that embodiment 1 obtains；
Fig. 3 is the chromatograms of Diphenylheptane constituents in the sample 1 that embodiment 1 obtains.
Embodiment
To be that embodiment is further described in detail to technical scheme below.It should be understood, however, that this
The protection domain of invention is not limited to these embodiments.
Embodiment 1
Prepared by Rhizoma Alpiniae Officinarum effective site sample 1
Take Rhizoma Alpiniae Officinarum 1KG, plus 8 times amount, 85% ethanol extraction 3 times, 2 h every time, filtration, merging filtrate, reclaim ethanol, add water and make to contain
Alcohol amount 40%, stands 12h, filters, and after the ethanol dissolving that solid adds 50%, filters, by D101 macroporous resin column, washes, 50%
After ethanol elution, 85% ethanol elution, collect 85% ethanol elution, reclaim ethanol, filter, filtrate with 60% ethanol weight
Crystallization, is dried, obtains 21 grams of Rhizoma Alpiniae Officinarum effective site samples 1, wherein galangin content 53.6%, nimbecetin -4 '-O- methyl ether contains
Amount 4.69%, galangin -3-O- methyl ether content 9.4%, 1- phenyl -7-（3 '-methoxyl group -4 '-hydroxyl）- 5- alcohol -3- heptanone contains
Amount 5.8%.
Embodiment 2
Prepared by Rhizoma Alpiniae Officinarum effective site sample 2
Take Rhizoma Alpiniae Officinarum 1KG, plus 8 times amount, 95% ethanol extraction 3 times, 2 h every time, filtration, merging filtrate, reclaim ethanol, add water and make to contain
Alcohol amount 30%, stands 8h, filters, and after the ethanol dissolving that solid adds 60%, filters, by AB-8 macroporous resin column, washes, 50%
After ethanol elution, 95% ethanol elution, reclaims ethanol, filters, 50% ethyl alcohol recrystallization obtains dry the effective portion of Rhizoma Alpiniae Officinarum
Position 26g, dry 21 grams of Rhizoma Alpiniae Officinarum effective site samples 2, wherein galangin content 45.8%, nimbecetin -4 '-O- methyl ether contains
Amount 4.21%, galangin -3-O- methyl ether content 8.29%, 1- phenyl -7-（3 '-methoxyl group -4 '-hydroxyl）- 5- alcohol -3- heptanone
Content 7.8%.
Embodiment 3
Prepared by Rhizoma Alpiniae Officinarum effective site sample 3
Take Rhizoma Alpiniae Officinarum 1KG, plus 8 times amount, 75% ethanol extraction 3 times, 2 h every time, filtration, merging filtrate, reclaim ethanol, add water and make to contain
Alcohol amount 30%, stands 8h, filters, and after the ethanol dissolving that solid adds 60%, filters, by HPD-600 macroporous resin column, washes, 50%
Ethanol elution after, 95% ethanol elution, reclaim ethanol, filter, 50% ethyl alcohol recrystallization, be dried, obtain 24g Rhizoma Alpiniae Officinarum effective
Position sample 3, wherein galangin content 42.5%, nimbecetin -4 '-O- methyl ether content 3.56%, galangin -3-O- methyl ether contains
Amount 7.19%, 1- phenyl -7-（3 '-methoxyl group -4 '-hydroxyl）- 5- alcohol -3- heptanone content 7.2%.
Embodiment 4
The present embodiment provides the collection of illustrative plates of different preparation method effective site main components
Take the Rhizoma Alpiniae Officinarum ethyl acetate extract being equivalent to identical medical material amount and effective by the Rhizoma Alpiniae Officinarum of preparation method gained of the present invention
Position, the solution made, with high performance liquid chromatography to its main component galangin, nimbecetin -4 '-O- methyl ether, Rhizoma Alpiniae Officinarum
Element -3-O- methyl ether, 1- phenyl -7-（3 '-methoxyl group -4 '-hydroxyl）- 5- alcohol -3- heptanone is detected, obtains high-efficient liquid phase color
Spectrogram.As Figure 1-3.
In figure 1-4 chromatographic peak is respectively：Galangin, nimbecetin -4 '-O- methyl ether, galangin -3-O- methyl ether, 1-
Phenyl -7-（3 '-methoxyl group -4 '-hydroxyl）- 5- alcohol -3- heptanone, wherein 1,2,3 record under the conditions of 254nm, and 4 due to ultraviolet
Absorb weaker, therefore record under the conditions of 210nm, in ethyl acetate extract, 4 content is extremely low, therefore non-accompanying drawing, and of the present invention
In the effective site that preparation method is obtained, content is higher.As seen from the figure, under comparable sodium, Rhizoma Alpiniae Officinarum effective site mainly becomes
The content divided is more than ethyl acetate extract, illustrates that preparation method of the present invention has carried out richness to Rhizoma Alpiniae Officinarum effective site well
Collection, the effective site purity preparing is high.
Embodiment 5
The present embodiment provides the preparation of the medicine of Rhizoma Alpiniae Officinarum effective site preparation.
Take Rhizoma Alpiniae Officinarum 56KG, plus 6 times amount, 60% ethanol extraction 3 times, each 1.5h, filtration, merging filtrate, reclaim ethanol, plus
Water makes alcohol content 30%, stands 24h, filters, and after the ethanol dissolving that solid adds 45%, filters, by HPD-600 macroporous resin column,
Washing, after 50% ethanol elution, 80% ethanol elution, reclaims ethanol, filters, 80% ethyl alcohol recrystallization, be dried, obtain 1.2kg
Rhizoma Alpiniae Officinarum effective site, wherein galangin content 45.6%, nimbecetin -4 '-O- methyl ether content 3.81%, galangin -3-O-
Methyl ether content 7.95%, 1- phenyl -7-（3 '-methoxyl group -4 '-hydroxyl）- 5- alcohol -3- heptanone content 5.1%.Take this effective site
Finely ground, add Microcrystalline Cellulose 1.8kg, mix, pelletize, fill capsule, make 10000, aluminium-plastic bubble plate packing, obtain final product.
Embodiment 6
The present embodiment is verified to uric acid resisting activity in the effective site body of Rhizoma Alpiniae Officinarum.
（1）Kunming mouse, sub-cage rearing is in interior, room temperature（20～22 DEG C）, relative humidity 35%～50%, freely drink
Food, drinking-water.After adaptability is raised 5 days, start to be administered.120 Male Kunming strain mice, are randomly divided into 12 groups by body weight, every group
10, it is set to blank group, model group, allopurinol group, and 3 groups of Rhizoma Alpiniae Officinarum effective site sample variable concentrations extracts and is dried
Product.Above-mentioned 10 groups of animals, are placed in metabolic cage, free diet, drinking-water, and blank and model group gavage gives 0.5% CMC-Na, its
The daily gavage of its each group gives corresponding medicine, and dosage is as 0.2 mL/10g, successive administration 7 days.6th day, except sky
The white CMC-Na solution organizing lumbar injection 0.2 mL/10 g 0.5%, other each group lumbar injection Oteracil Potassium solution.7th day,
I.e. 1 h before last dose, the CMC-Na solution of blank group lumbar injection 0.2 mL/10g 0.5%, other each group lumbar injection oxygen
Piperazine acid potassium solution 0.2 mL/10 g, after 1 h, plucks eyeball and takes blood, and above-mentioned sample is pressed testing uric acid test kit respectively, added reaction examination
Agent, is measured.Test data with SPSS11.5 software statistics analyze, analysis result with± SD represents.
Can be seen that compared with model group from upper table result, 3 parts of Rhizoma Alpiniae Officinarum effective site samples all have obvious uric acid resisting
Effect, and be in dosage correlation, high dose is better than low dose group, and high dose group uric acid resisting effect is suitable with allopurinol matched group.
（2）Rhizoma Alpiniae Officinarum effective parts formulation is used for hyperuricemia to be observed
The capsule that embodiment 4 is obtained is used for 60 Patients with Hyperuricemias, wherein male 42, and in age 28-60 year, women 28
Example, age 25-64 year；Medicining mode：2 times a day, 2 every time, takes medicine 4 weeks.Criterion：Effective：Blood uric acid is close to normal
Or it decrease beyond before treatment 30%；Effectively：Blood uric acid has declined（Decline 10%-30%）；Invalid：Blood uric acid is dropped by less than 10%
Or increase.Effective 45 of result, effective 15, invalid 0.
Claims (10)
1. a kind of effective ingredient in Chinese of uric acid resisting, it is to extract in Rhizoma Alpiniae Officinarum to separate the total flavones obtaining and Diphenylheptane class
Composition.
2. the effective ingredient in Chinese of uric acid resisting according to claim 1, its composition comprises galangin, galangin -3- first
Ether, kaempferol -4 '-methyl ether and 1- phenyl -7-（3 '-methoxyl group -4 '-hydroxyl）- 5- alcohol -3- heptanone.
3. according to claim 2 uric acid resisting effective ingredient in Chinese it is characterised in that：Height is contained in this effective ingredient in Chinese
Alpinin 35wt%-80wt%, galangin -3-O- methyl ether 5wt%-14wt%, kaempferol -4 '-O- methyl ether 1wt%-7wt%, 1- benzene
Base -7-（3 '-methoxyl group -4 '-hydroxyl）- 5- alcohol -3- heptanone 2wt%-10wt%, its summation is less than 100%.
4. the preparation method of the effective ingredient in Chinese of uric acid resisting described in a kind of any one of claim 1-3, it includes walking as follows
Suddenly：
Take galangal rhizome to be raw material, with ethanol as solvent extraction, obtain Rhizoma Alpiniae Officinarum alcohol extract；
Rhizoma Alpiniae Officinarum alcohol extract is reclaimed ethanol or adds water, so that precipitation is precipitated, standing, leaching precipitate, obtain Rhizoma Alpiniae Officinarum effective site
Crude product；
Rhizoma Alpiniae Officinarum effective site crude product is added after ethanol solution dissolving, carries out separating using macroporous resin column, with water and ethanol be
Mobile phase carries out eluting, collects active site, and to its decompression and solvent recovery, after separating out precipitation, filters, be dried, recrystallization is
Obtain Rhizoma Alpiniae Officinarum effective site.
5. according to claim 4 preparation method it is characterised in that this preparation method comprises the steps：
Take galangal rhizome to be raw material, with 50%-95% ethanol solution 6-10 times amount reflux, extract, 2-4 time, each 1-3 hour, obtain
To Rhizoma Alpiniae Officinarum alcohol extract；
Rhizoma Alpiniae Officinarum alcohol extract is reclaimed ethanol or adds water to alcohol content less than 50%, so that precipitation is precipitated, stand more than 6 hours, leaching
Precipitate, obtains Rhizoma Alpiniae Officinarum effective site crude product；
Rhizoma Alpiniae Officinarum effective site crude product is added after the dissolving of 45%-65% ethanol solution, carries out separating using macroporous resin column, use successively
Water, 50% ethanol solution, 65%-90% ethanol solution carry out eluting, collect alcohol content 65%-90% ethanol solution eluting position, and right
Its decompression and solvent recovery, after separating out precipitation, filters, is dried, then with 50%-90% ethanol solution recrystallization, obtains final product Rhizoma Alpiniae Officinarum effective
Position.
6. preparation method according to claim 4 it is characterised in that：Big pore resin includes various nonpolar macroporous trees
Fat, low pole macroporous resin or polar macroporous resin.
7. the preparation method according to claim 5 or 6 it is characterised in that：Big pore resin includes D101 type macropore tree
Fat and/or AB-8 type macroporous resin.
8. a kind of medicine, it comprises the effective ingredient in Chinese of the uric acid resisting described in any one of claim 1-3.
9. the application of the Drug therapy hyperuricemia described in claim 8 or gout.
10. the combination of the medicine described in claim 8 and pharmaceutically acceptable carrier, described pharmaceutically acceptable carrier bag
Include sugar alcohol, aminoacid, injection Vitamin B_6 DTA disodium, Ethylenediaminetetraacetic Acid Calcium Salt, inorganic salt, stearate, mineral acid, acylate, sugar and
The group of one or more of its derivant, cellulose and its derivates, silicon derivative, surfactant and phospholipid material
Close；
Described sugar alcohol includes the combination of one or more of Mannitol, Sorbitol, xylitol；
Described aminoacid includes the combination of one or more of Cysteine Hydrochloride, Methionine, glycine；
Described inorganic salt includes the alkali-metal carbonate of monovalence, the alkali-metal acetate of monovalence, the alkali-metal phosphate of monovalence, chlorine
Change one or more of sodium, potassium chloride, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, Calcium Carbonate, calcium bicarbonate
Combination；
Described stearate includes calcium stearate he/ or magnesium stearate；
Described mineral acid includes the combination of one or more of hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid；
Described acylate includes sodium lactate；
Described carbohydrates and their derivative is included as in maltose, glucose, Fructose, dextran, sucrose, Lactose, cyclodextrin, starch
The combination of one or more；
Described silicon derivative includes the combination of one or more of alginate, gelatin, Polyvinylpyrrolidone, glycerol, agar
Described surfactant includes Tween 80 and/or Polyethylene Glycol；
Described phospholipid material includes Kaolin and/or Pulvis Talci.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611009850.3A CN106421589A (en) | 2016-11-17 | 2016-11-17 | Traditional Chinese medicinal effective part for decreasing uric acid as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611009850.3A CN106421589A (en) | 2016-11-17 | 2016-11-17 | Traditional Chinese medicinal effective part for decreasing uric acid as well as preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106421589A true CN106421589A (en) | 2017-02-22 |
Family
ID=58219953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611009850.3A Pending CN106421589A (en) | 2016-11-17 | 2016-11-17 | Traditional Chinese medicinal effective part for decreasing uric acid as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106421589A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108095096A (en) * | 2017-12-29 | 2018-06-01 | 董占斌 | The composition and preparation method of a kind of anti-trioxypurine |
| CN108404020A (en) * | 2018-05-22 | 2018-08-17 | 华南理工大学 | A kind of composition with anti-trioxypurine function containing galangal rhizome extract and chrysanthemum extract and its application |
| CN108686152A (en) * | 2018-08-13 | 2018-10-23 | 武汉轻工大学 | Application of the galangal rhizome extract in preparing the drug and/or health products for the treatment of pneumonia and/or pulmonary fibrosis |
| CN108882744A (en) * | 2016-04-08 | 2018-11-23 | 韩国韩医学研究院 | Contain intelligence development extract as effective component for preventing, improving or treating the composition of hyperuricemia or dysbolism relevant to hyperuricemia |
| CN110236997A (en) * | 2019-06-20 | 2019-09-17 | 佛山市普达美生物医药科技有限公司 | A kind of composition and preparation method thereof with whitening function |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101002762A (en) * | 2006-12-26 | 2007-07-25 | 广东药学院 | Application of galangin for treating irritable bowel syndrome, and its extraction method |
| CN101125136A (en) * | 2006-12-26 | 2008-02-20 | 广东药学院 | Application of alpinia officinarum hance diarylheptanes compound in pain-alleviating and anti-inflammatory and its extracting method |
| CN102048993A (en) * | 2009-10-29 | 2011-05-11 | 中国中医科学院中药研究所 | Application of galangal extract in preparation of medicine for inhibiting calcium channel |
| CN104547826A (en) * | 2015-01-05 | 2015-04-29 | 海南医学院 | Medical application of galangin extract to treat dysmenorrhea |
| CN104906483A (en) * | 2015-05-26 | 2015-09-16 | 南京泽朗医药科技有限公司 | Technology for extracting galangal total flavonoids |
| CN106045960A (en) * | 2016-05-27 | 2016-10-26 | 中国热带农业科学院农产品加工研究所 | Method of extracting diphenyl heptane substance from galangal |
-
2016
- 2016-11-17 CN CN201611009850.3A patent/CN106421589A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101002762A (en) * | 2006-12-26 | 2007-07-25 | 广东药学院 | Application of galangin for treating irritable bowel syndrome, and its extraction method |
| CN101125136A (en) * | 2006-12-26 | 2008-02-20 | 广东药学院 | Application of alpinia officinarum hance diarylheptanes compound in pain-alleviating and anti-inflammatory and its extracting method |
| CN102048993A (en) * | 2009-10-29 | 2011-05-11 | 中国中医科学院中药研究所 | Application of galangal extract in preparation of medicine for inhibiting calcium channel |
| CN104547826A (en) * | 2015-01-05 | 2015-04-29 | 海南医学院 | Medical application of galangin extract to treat dysmenorrhea |
| CN104906483A (en) * | 2015-05-26 | 2015-09-16 | 南京泽朗医药科技有限公司 | Technology for extracting galangal total flavonoids |
| CN106045960A (en) * | 2016-05-27 | 2016-10-26 | 中国热带农业科学院农产品加工研究所 | Method of extracting diphenyl heptane substance from galangal |
Non-Patent Citations (3)
| Title |
|---|
| 卜宪章等: "高良姜化学成分研究", 《中药材》 * |
| 陈平: "高良姜的提取工艺及成分分析研究", 《中国优秀硕士学位论文全文数据库电子期刊》 * |
| 黎莉等: "中药提取物中黄嘌呤氧化酶抑制剂的筛选", 《武汉工程大学学报》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108882744A (en) * | 2016-04-08 | 2018-11-23 | 韩国韩医学研究院 | Contain intelligence development extract as effective component for preventing, improving or treating the composition of hyperuricemia or dysbolism relevant to hyperuricemia |
| CN108882744B (en) * | 2016-04-08 | 2022-04-19 | 韩国韩医学研究院 | Composition containing fructus alpiniae oxyphyllae extract and application of fructus alpiniae oxyphyllae extract |
| CN108095096A (en) * | 2017-12-29 | 2018-06-01 | 董占斌 | The composition and preparation method of a kind of anti-trioxypurine |
| CN108404020A (en) * | 2018-05-22 | 2018-08-17 | 华南理工大学 | A kind of composition with anti-trioxypurine function containing galangal rhizome extract and chrysanthemum extract and its application |
| CN108686152A (en) * | 2018-08-13 | 2018-10-23 | 武汉轻工大学 | Application of the galangal rhizome extract in preparing the drug and/or health products for the treatment of pneumonia and/or pulmonary fibrosis |
| CN110236997A (en) * | 2019-06-20 | 2019-09-17 | 佛山市普达美生物医药科技有限公司 | A kind of composition and preparation method thereof with whitening function |
| CN110236997B (en) * | 2019-06-20 | 2022-06-21 | 佛山市普达美生物医药科技有限公司 | Composition with whitening effect and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106421589A (en) | Traditional Chinese medicinal effective part for decreasing uric acid as well as preparation method and application thereof | |
| US10624938B2 (en) | Total flavone extract of flower of abelmoschus manihot L. medic and preparation method thereof | |
| TWI454269B (en) | Compounds isolated from xanthoceras sorbifolia, methods for preparing same and uses thereof | |
| RU2668955C2 (en) | New salvianolic acid compound t, preparation method therefor and use thereof | |
| JP2013535500A (en) | Urushi extract with increased content of active flavonoid compound and method for producing the same | |
| WO2010028596A1 (en) | The pharmaceutical composition containing ferulic acid and matrine compounds, the preparation and the use thereof | |
| JP4516282B2 (en) | Novel substance having α-glucosidase inhibitory activity and food containing the same | |
| CN106905281B (en) | Inhibit acetyl and the flavone compound of butyrylcholine esterase and application thereof in thick fruit precipice beans rattan | |
| CN101524422B (en) | Health products with hypolipemic function, preparation method and usage thereof | |
| WO2008145064A1 (en) | The method for a sequoyitol-containing extract obtaining from the genus of trifolium, sobyean and ginkgo biloba and use thereof | |
| CN108610387B (en) | Four isoflavan glycosides compounds with nerve cell protection activity and preparation method thereof | |
| CN114209739A (en) | Application of pulsatilla chinensis extract in preparation of antidepressant drug | |
| CN103860638A (en) | Preparation method of sophora alopecuroide flavonoid composition and new medical application | |
| EP3160456B1 (en) | 7-hydroxy cannabidiol (7-oh-cbd) for use in the treatment of non-alcoholic fatty liver disease (nafld) | |
| JP2000154151A (en) | Immunosuppressant | |
| AU2010222963A1 (en) | Estrogenic compounds and their methods of use | |
| WO2009062374A1 (en) | The pharmaceutical use of liquiritigenin for preparing medicine for treating neurodegenerative diseases | |
| CN105012294B (en) | New application of the ellagic acid compounds in treatment antihyperuricemic disease drug is prepared | |
| WO2009031826A1 (en) | Process for preparing vitis vinifera pip extract and pharmaceutical composition for preventing or treating rheumatoid arthritis comprising the same | |
| WO2008091064A1 (en) | Composition comprising trachelospermi caulis and pyrola japonica extracts for the treatment and prevention of inflammatory diseases | |
| CN102641342A (en) | Traditional Chinese medicine extract for treating nephropathy and preparation method | |
| CN109091602A (en) | Semen allii tuberosi effective component, extracting method and its application in terms of liver injury medicament is protected in preparation | |
| CN103285072A (en) | Hyperoside-containing extract and medical application thereof | |
| US11219613B2 (en) | Pharmaceutical composition for preventing and treating liver diseases, containing, as active ingredient, cromolyn or pharmaceutically acceptable salt thereof | |
| CN114409544B (en) | Phenylpropanoid with vasodilation activity, and extraction method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170222 |